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Abstract
Background: Carﬁlzomib and other proteasome inhibitors (PIs) have revolutionized treatment of multiple myeloma
(MM). PIs have proven to be highly effective, but are associated with signiﬁcant cardiovascular adverse events (AEs). No
prior study has compared the cardiotoxicity of carﬁlzomib against other PI's and all other classes of medications.
Objectives: The purpose of this study is to characterize the cardiotoxicity of carﬁlzomib with respect to other PIs and all
classes of medications using the US Food and Drug Administration Adverse Events Reporting System (FAERS) database
and to deﬁne the observed cardiotoxicity proﬁle.
Methods: The FAERS database was queried between years 2017 and 2020 to identify AEs associated with PIs. Data
extracted included concomitant medications used, type and severity of AEs and patient characteristics including age, sex,
and time from medication initiation to adverse event. Cardiotoxicities assessed included acute myocardial infarction,
heart failure, and supraventricular tachycardia. The reporting odds ratio (ROR) and information component assessed the
strength of association between PIs and cardiotoxicity.
Results: Over the study period, 21,026 adverse events were reported in patients taking carﬁlzomib among 55,195 total
adverse events in patients taking PI's were identiﬁed from 6,548,048 total events reported in the FAERS database. The
most common AE associated with carﬁlzomib was development of heart failure (1116 adverse events); disproportionality
analysis revealed a stronger association with hypertension and QT prolongation with carﬁlzomib than other PI's.
Conclusions: While they have demonstrated efﬁcacy and revolutionized treatment of MM, carﬁlzomib and other PI's
are associated with cardiotoxicities.
Keywords: Cardio-oncology, Epidemiology, Adverse events

1. Introduction

C

arﬁlzomib is a second-generation proteasome
inhibitor (PI), a class of medications that has
revolutionized treatment of multiple myeloma
(MM). It is derived from epoxomicin and irreversibly binds the 20S proteasome eventually leading to
cell death in patients with MM [12]. Carﬁlzomib
initially received fast track status from the United
States Food and Drug Administration (FDA) in
January 2011 before being approved in 2012 for use
in refractory MM [12]. Following FDA approval, its
clinical use has grown dramatically due to

demonstrated clinical efﬁcacy, such as a recent
study showing that when used in conjunction
with dexamethasone, it has demonstrated proved
progression-free survival in patients with relapsed
or refractory multiple myeloma compared to
the combination of bortezomib and dexamethasone
[5].
Despite the remarkable efﬁcacy of PIs (carﬁlzomib, bortezomib, and ixazomib) in treating MM,
these medications also cause signiﬁcant cardiovascular adverse events. Therefore, cardiotoxicity and
especially cardiac failure are now considered class
effects of proteasome inhibitors. However, patients
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with MM commonly have risk factors for cardiac
events attributable to patient-speciﬁc characteristics, MM itself and MM treatment, demonstrated
in both clinical trials and meta-analyses. Further
analyses of large datasets may help identify how
each of these factors contribute to cardiac event
risk. To date, no administrative database studies has
been performed. The purpose of this study is to
characterize further the cardiotoxicity of carﬁlzomib
with respect to other PIs and all other classes of
medications and to leverage the large sample size of
a US administrative database to identify previously
unreported cardiotoxicities and better deﬁne the
cardiac risk proﬁle of these medications.

2. Methods
The US Food and Drug Administration Adverse
Events Reporting System (FAERS) database was
retrospectively queried from years 2017 through
2020 to identify adverse events associated with
proteasome inhibitors (PIs). The FAERS is a database documenting greater than 15 million adverse
event reports, medication error reports and medication quality complaints submitted to the FDA
since inception in 1968; reports since 2004 are publicly available from the FDA's website. Each report
includes a case identiﬁcation number used to link
ﬁles within the database and identify updates to
prior reports. Medical information contained in the
database includes concomitant medications used,
type of adverse reaction, and the severity of the reaction. Routine demographic information such as
age, sex, geographic region of report, type of reporter (health care professional, consumer, pharmaceutical company or unknown) and the time
from medication to adverse event are included in
the database. The database is a registry of all submissions to the FAERS system.
This analysis included all reports of adverse
events attributed to carﬁlzomib, bortezomib and
ixazomib. The database was queried from January 1,
2017 to December 31, 2020. These dates were
selected to minimize bias: 2016 was the ﬁrst full year
ixazomib was available on the market and 2020 was
the last year the full database was available at the
time of analysis. Cardiotoxic events were identiﬁed
by the listed MedDRA preferred term, and were
grouped into myocardial infarction, hypertension,
heart failure, arrhythmia events, pericardial effusion
and QTc prolongation. Cardiotoxic events which
were life-threatening, necessitating hospitalization,
or led to death or disability were considered as severe. The MedDRA database is a hierarchical database which organizes medical symptoms and
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diseases into pertinent organ systems. MedDRA
terms used to identify adverse reactions are listed in
Table 4. To reduce bias from including multiple
reports per patient, when multiple reports were
recorded from the same patient, only the ﬁnal report
was included in this analysis. The database was
accessed March 21, 2021. Dyspnea was not included
as a cardiotoxic effect due to the potential for it to
represent cardiotoxicity (for example, as a manifestation of heart failure) or non-cardiac toxicity (for
example, pulmonary, renal or thyroid toxicity),
consistent with other studies [21].
Patients taking a PI were identiﬁed from the
database and categorized as taking carﬁlzomib,
other PIs, carﬁlzomib and other PI or no PI. Characteristics of patients taking carﬁlzomib are presented using summary statistics. To further
characterize patients and the reactions associated
with carﬁlzomib, all patients on carﬁlzomib were
included single cohort, regardless of concomitant
use of other PI. The severity of reaction was
dichotomized into serious and non-serious using
FAERS-supplied criteria.
A disproportionality analysis was performed to
assess cardiotoxicity risk using the reporting odds
ratio (ROR) and information component (IC). The
ROR measures the association between a speciﬁc
exposure (medication) and odds of developing a
speciﬁc outcome (cardiotoxic event) and is deemed
statistically signiﬁcant if its 95% conﬁdence interval
does not include 1.0. This methodology has been
employed with multiple antineoplastic agents,
including ibrutinib [18,23] and osimertinib [1]. The
IC, described by Bate et al. and ﬁrst applied to
pharmacovigilance by the Uppsala Monitoring
Group [2], is calculated


nobs þ 0:5
IC ¼ log 2
nexpected þ 0:5
In this equation, nobs represents the number of
observed events and nexpected represents the number
of expected events; IC025 representing the lower
bound of a 95% credibility interval of the IC and an
association is deemed statistically signiﬁcant when
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the IC025 > 0. The IC method for disproportionality
analysis has been used by other groups to describe
cardiotoxic effects of ibrutinib [18] and the class of
checkpoint inhibitors [4]. Adverse events classiﬁed
as cardiotoxic were acute hypertension, dyspnea,
edema, heart failure, myocardial infarction, any
arrhythmia, and QT prolongation. The risk of carﬁlzomib-associated cardiotoxicity was compared
with other PIs and all other entries in the database.
Time-to-adverse event data, when available, is reported as median and interquartile range (IQR). All
analyses were performed using SAS software
version 9.4 (SAS Institute, Cary, North Carolina).

3. Results
Over the three years evaluated, 6,548,048 adverse
events were reported in the FAERS database, 55,195
of which were observed in patients taking PI's.
There were 19,486 adverse events reported in patients taking carﬁlzomib and no other PI, 34,169 in
patients taking other PI's and 1540 in patients taking
carﬁlzomib and at least one additional PI. Characteristics of patients on these medications are
described in Table 1. Among patients on carﬁlzomib
without other PI, 2893 (14.8%) adverse events were
classiﬁed as acute myocardial infarction, heart failure, arrhythmia (both supraventricular and ventricular), pericardial disease or hypertension; among
patients on other PI's, 2373 (6.9%) adverse events
were categorized as one of these cardiotoxic categories; among patients on a combination of carﬁlzomib and other PI, 221 (14.4%) adverse events were
categorized as one of these cardiotoxic categories.
Adverse cardiac events related to proteasome inhibitors reported in FAERS database over this interval are listed in Table 2.
Among 21,026 adverse events associated with
carﬁlzomib use, approximately 54.1% (with sex reported) were observed in males. Approximately
45.4% of adverse events were considered serious. In
44.7% of the cases, adverse events necessitated
hospitalization, were life-threatening, or led to
death. Among the 3034 patients with time-to-event
data available, a median of 64 (IQR 10-188) days
elapsed between initiation of carﬁlzomib and the
adverse event.
The most common cardiotoxic event associated
with carﬁlzomib was development of heart failure
(1116 adverse events), representing 5.3% of all carﬁlzomib-associated adverse events. Of these, 1065
(95.4%) adverse events were associated with carﬁlzomib and 51 (4.6%) were associated with a combination of carﬁlzomib and another medication.
Additionally, 764 (68.5%) of these adverse events

were serious. For those patients with time-to-event
data available, the median time to event was 31 (IQR
9-70) days.
Hypertension was the second most common reported cardiotoxicity associated with carﬁlzomib,
with 694 adverse events recorded in the FAERS
database. This represented 3.3% of all adverse reactions associated with carﬁlzomib. Of these, 663
(95.5%) were associated solely with carﬁlzomib and
31 (4.5%) were reported in patients taking a combination of carﬁlzomib and another medication.
Approximately 51.4% (357) of the adverse events
due to hypertension were serious. Among patients
with time-to-event data available, the median time
to event was 8 (IQR 1e14.5) days.
The disproportionality analysis revealed carﬁlzomib had a stronger association with hypertension
than other PI's with a ROR of 4.6 (95% conﬁdence
interval: 4.0e5.4), QT prolongation with ROR 6.9
(95% conﬁdence interval: 4.9e9.7) and heart failure
with ROR 2.7 (95% conﬁdence interval: 2.5e3.0),
respectively. The reporting odds ratios for all PI's
are listed in Table 3 and illustrated in Fig. 1a. When
compared to the full database, carﬁlzomib was
associated with higher risk of heart failure (ROR 5.6,
95% conﬁdence interval 5.3e6.0), QT prolongation
(ROR 4.9, 95% conﬁdence interval 4.2e5.7), and
pericardial effusion (ROR 3.6, 95% conﬁdence interval 3.0e4.3). Toxicities with the highest IC were
heart failure (IC ¼ 2.443, IC025 ¼ 2.353) and QT
prolongation (IC ¼ 2.216, IC025 ¼ 1.991); all calculated IC and IC025 are depicted in Fig. 1b.
Dyspnea and edema were not considered as cardiotoxicities due to the potential of both cardiac and
noncardiac dysfunction to cause them. Nevertheless, this analysis identiﬁed 1481 (7.0% of all carﬁlzomib-related adverse reactions) cases of dyspnea
and 486 (2.3% of all carﬁlzomib-related adverse reactions) cases of edema. The association between
carﬁlzomib and these reactions were relatively
weak: disporportionality analysis revealed ROR of
1.8 (95% conﬁdence interval 1.7e1.9) and IC 0.69
(IC025 ¼ 0.61) for dyspnea and ROR 1.0 (95% conﬁdence interval 0.9e1.1) and IC -0.21 (IC025 ¼ 0.35)
for edema.

4. Discussion
Analysis of FAERS database revealed that 13.5% of
all adverse events associated with carﬁlzomib were
cardiac related. When compared to all other medications in FAERS, carﬁlzomib was associated with
higher risk of heart failure, pericardial effusion and
QT prolongation (Table 2). The ROR was highest for
heart failure, followed by QTc prolongation and then

Table 1. Characteristics of patients with cardiac adverse event related to proteasome inhibitor.
Characteristic

All Events
n ¼ 19486

Age (years)
Sex
F
M
Time to AE (days)
Serious AE
AE Severity
Death
Disabled
Hospitalized
Life Threatening
Other Serious
Nonserious
AE Caused by
Carﬁlzomib
Year of AE
2017
2018
2019
2020
AE Reported by
Professional
Region of AE
Asia
Americas
Europe
Australia
Africa

65.53 ± 11.25
7257 (40.8%)
10512 (59.2%)
60 (10e175)
8735 (44.8%)

ACS

Any
Arrhythmia

Heart Failure Hypertension Pericardial
Effusion

Dyspnea

Edema

n ¼ 362

n ¼ 753

n ¼ 1065

n ¼ 663

n ¼ 50

n ¼ 1276

n ¼ 373

67.33 ± 8.4

65.79 ± 12.13 67.92 ± 10.67

68.55 ± 8.28

67.97 ± 8.83 65.86 ± 10.15 65.9 ± 9.75

70 (22.5%)
241 (77.5%)
13 (3e42)
321 (88.7%)

202 (29.4%)
484 (70.6%)
32 (8e99)
559 (74.2%)

420 (44%)
535 (56%)
31 (8e67)
732 (68.7%)

278 (47%)
313 (53%)
8 (1e12)
333 (50.2%)

30 (69.8%)
13 (30.2%)
2 (2e2)
31 (62%)

541 (46.1%)
633 (53.9%)
35 (3e156)
899 (70.5%)

149 (43.3%)
195 (56.7%)
2 (2e14)
156 (41.8%)

2381 (12.2%)
145 (0.7%)
5094 (26.1%)
1113 (5.7%)
2 (0%)
10751 (55.2%)
11331 (58.1%)

136 (37.6%)
0 (0%)
129 (35.6%)
56 (15.5%)
0 (0%)
41 (11.3%)
269 (74.3%)

256 (34%)
3 (0.4%)
209 (27.8%)
91 (12.1%)
0 (0%)
194 (25.8%)
559 (74.2%)

208 (19.5%)
4 (0.4%)
390 (36.6%)
130 (12.2%)
0 (0%)
333 (31.3%)
790 (74.2%)

55 (8.3%)
0 (0%)
217 (32.7%)
61 (9.2%)
0 (0%)
330 (49.8%)
496 (74.8%)

15 (30%)
0 (0%)
9 (18%)
7 (14%)
0 (0%)
19 (38%)
43 (86%)

211 (16.5%)
39 (3.1%)
515 (40.4%)
134 (10.5%)
0 (0%)
377 (29.5%)
865 (67.8%)

42 (11.3%)
8 (2.1%)
84 (22.5%)
22 (5.9%)
0 (0%)
217 (58.2%)
278 (74.5%)

5060 (26%)
8340 (42.8%)
2902 (14.9%)
3184 (16.3%)
17535 (90%)

116 (32%)
85 (23.5%)
104 (28.7%)
57 (15.7%)
322 (89%)

218
214
174
147
681

331
377
218
139
975

(31.1%)
(35.4%)
(20.5%)
(13.1%)
(91.5%)

157 (23.7%)
273 (41.2%)
136 (20.5%)
97 (14.6%)
608 (91.7%)

30 (60%)
10 (20%)
6 (12%)
4 (8%)
46 (92%)

336 (26.3%)
493 (38.6%)
241 (18.9%)
206 (16.1%)
1080 (84.6%)

83 (22.3%)
172 (46.1%)
62 (16.6%)
56 (15%)
343 (92%)

341 (1.8%)
7839 (41.2%)
10867 (96.6%)
320 (81.4%)
3 (1.2%)

7 (1.9%)
91 (25.7%)
250 (90.6%)
13 (44.8%)
0 (0%)

18 (2.4%)
217 (29.9%)
493 (91.3%)
14 (25.5%)
1 (0.7%)

21 (2%)
271 (26.1%)
751 (94%)
17 (30.4%)
0 (0%)

21 (3.2%)
219 (34.5%)
405 (95.7%)
10 (52.6%)
0 (0%)

0 (0%)
16 (33.3%)
30 (88.2%)
2 (33.3%)
0 (0%)

32 (2.6%)
613 (50.2%)
576 (89.4%)
32 (45.1%)
1 (0.5%)

6 (1.6%)
197 (54%)
165 (97.1%)
3 (42.9%)
0 (0%)

(29%)
(28.4%)
(23.1%)
(19.5%)
(90.4%)

Abbreviation: AE ¼ Adverse Event. Notes: Values in this table are reported as n (%) or mean ± standard deviation. Values of N may vary
due to data missing from the database.

pericardial effusion. In comparison to other PIs,
carﬁlzomib was associated higher ROR for QT prolongation, followed by hypertension and then pericardial effusion. Previous work demonstrated an
association between MM and cardiac events in patients undergoing treatment for MM, though prior
studies have been unable to differentiate whether
the association was explained by patient-characteristics, MM itself or MM treatment [11]. This work
demonstrates that at least part of this association is
explained by treatment agent, with carﬁlzomib
having a higher ROR than other PIs.

Cardiotoxicity, particularly cardiac failure, was
ﬁrst reported as an adverse event associated with
carﬁlzomib, but it is now considered as a class effect
of the PIs following reports of cardiotoxicity resulting from bortezomib and ixazomib [10,13]. In clinical trials, there was an 18.2% rate of any
cardiovascular adverse event (event rates ranged
from 0% to 52%) and an 8.2% risk (events ranged
from 0% to 45%) of high-grade cardiovascular
adverse events [6,21]. Moreover, the addition of
carﬁlzomib to a regimen of lenalidomide and
dexamethasone was associated with an increase in

Table 2. Adverse events related to proteasome inhibitors reported in FAERS database between 2017 and 2020.
Event

All PIs

Carﬁlzomib

Other PIs

Carﬁlzomib þ Other PIs

No PIs

All Adverse Events
ACS
Any Arrhythmia
Heart Failure
Hypertension
Pericardial Effusion
Dyspnea
Edema

55,195
753 (1.4%)
1802 (3.3%)
1807 (3.3%)
943 (1.7%)
182 (0.3%)
3011 (5.5%)
1490 (2.7%)

19,486
362 (1.9%)
753 (3.9%)
1065 (5.5%)
663 (3.4%)
50 (0.3%)
1276 (6.5%)
373 (1.9%)

24,169
377 (1.1%)
1006 (2.9%)
691 (2%)
249 (0.7%)
50 (0.1%)
1530 (4.5%)
1004 (2.9%)

1540
14 (0.9%)
43 (2.8%)
51 (3.3%)
31 (2%)
82 (5.3%)
205 (13.3%)
113 (7.3%)

6,492,853
60,237 (0.9%)
140,888 (2.2%)
63,893 (1%)
137,219 (2.1%)
11,434 (0.2%)
263191 (4.1%)
143086 (2.2%)

Abbreviations: ACS ¼ Acute Coronary Syndrome, PI ¼ Proteasome inhibitor.
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Table 3. Reporting Odds Ratios and Information Criteria of selected toxicities associated with proteasome inhibitors reported in FAERS database
between 2017 and 2020.
Adverse Event

Carﬁlzomib vs Full Database

Carﬁlzomib vs PI's

ROR (95% CI)

IC (IC_025-IC-975)

ROR (95% CI)

IC (IC_025-IC-975)

Acute Coronary Syndrome
Any Arrhythmia
Heart Failure
Hypertension
Pericardial Effusion
QT Prolongation
Dyspnea
Edema

1.94
1.77
5.61
1.59
3.58
4.91
1.79
1.05

0.99 (0.84e1.14)
0.83 (0.72e0.93)
2.44 (2.35e2.53)
0.69 (0.58e0.8)
0.53 (0.13e0.92)
2.22 (1.99e2.44)
0.69 (0.61e0.77)
0.21 (0.35e0.06)

1.63 (1.41e1.88)
1.3 (1.18e1.43)
2.72 (2.47e2.99)
4.65 (4.02e5.38)
4.31 (3.11e5.97)
6.9 (4.93e9.66)
1.62 (1.5e1.74)
0.78 (0.7e0.87)

0.44 (0.26e0.63)
0.24 (0.12e0.37)
0.74 (0.63e0.85)
0.99 (0.85e1.14)
0.36 (0.81 - 0.09)
1.04 (0.75e1.34)
0.26 (0.17e0.36)
0.5 (0.66e0.33)

(1.75e2.15)
(1.65e1.9)
(5.28e5.96)
(1.47e1.71)
(3.02e4.26)
(4.23e5.7)
(1.7e1.89)
(0.96e1.15)

Abbreviations: ROR ¼ Reporting Odds Ratio, IC ¼ Information Criterion, 95% CI ¼ 95% conﬁdence interval.

the rate of cardiac failure of any severity from 4.1%
to 6.4%, severe cardiac failure from 1.8% to 3.8% and
ischemic heart disease (3.3% versus 2.1%) [20].
Likewise, a study evaluating carﬁlzomib with
cyclophosphamide against corticosteroid with
cyclophosphamide noted an increase in the rate of
cardiac failure of any severity from 1% to 5% and
Table 4. MedDRA terms used to identify cardiovascular toxicities.
Cardiac Condition

MedDRA Term

Acute Coronary Syndrome

Acute myocardial infarction
Coronary artery disease
Acute myocardial infarction
Acute coronary syndrome
Coronary artery stenosis
Myocardial infarction
Coronary artery occlusion
Angina pectoris
Angina unstable
Myocardial ischemia
Arteriospasm coronary
Microvascular coronary
artery disease
Cardiac failure acute
Cardiac failure congestive
Ejection fraction decreased
Cardiac failure
Cardiomyopathy
Left ventricular failure
Ventricular hypokinesia
Myocarditis
Right ventricular failure
Cardiogenic shock
Cardiac failure chronic
Cardiotoxicity
Stress cardiomyopathy
Cytotoxic cardiomyopathy
Cardiac failure congestive
Left ventricular dysfunction
Atrial ﬂutter
Atrial ﬁbrillation
Supraventricular tachycardia
Supraventricular tachycardia
Cardiac tamponade
Pericardial effusion
Electrocardiogram
QT prolongation

Acute Heart Failure

Supraventricular Tachycardia

Pericardial Effusion
QTc Prolongation

severe cardiac failure from 1% to 2% [8]. Dimopolos
et al. also demonstrated carﬁlzomib has a more
dangerous cardiotoxicity proﬁle than bortezomib,
with carﬁlzomib demonstrating increased rates of
cardiac failure (8% versus 2.8%) and ischemic
heart disease (2.5% versus 2%) when compared to
bortezomib and dexamethasone [5]. Bortezomibassociated cardiotoxicity has also been shown in
animal models [15,17]. Multiple reports have
demonstrated an array of adverse events with bortezomib [3,9] and more recently ixazomib [10],
though a recent study by Richardson et al. did
not support these ﬁndings [14]. Conversely, a study
by Kastritis et al. showed a reversible reduction in
left ventricular ejection fraction in 12% of MM
patients receiving carﬁlzomib [5]. The present study
is consistent with most of the current evidence
demonstrating increased risk of cardiotoxicity with
carﬁlzomib. Furthermore, the study revealed a
higher rate of myocardial infarction and heart failure with carﬁlzomib when compared to other PIs.
The pathophysiology of carﬁlzomib-mediated
cardiotoxicity is incompletely understood, despite
evaluation of it and other PIs in multiple studies
[15]. A metaanalysis performed by Rahman et al.
found a pooled RR of 2.34 (95% CI 1.66e3.32,
P < 0.00001) of heart failure among those treated
with carﬁlzomib vs controls in four phase III randomized controlled trials [16], while a metaanalysis
performed by Shah et al. found a pooled RR of 2.03
(95% CI 1.19e3.46, p ¼ 0.010) of cardiotoxicity
among those treated with carﬁlzomib compared to
controls [19]. Following this, a mouse model
revealed treatment with carﬁlzomib was associated
with diminished proteasomal activity in the heart,
postulated to cause reduction of left ventricular
systolic function and prophylactic metformin
tempered this effect [7]. In the same study, carﬁlzomib was also associated with enhanced protein
phosphatase 2 activity and decreased downstream
AMP-activated protein kinase activity. Other work
has suggested proteasome inhibition leads to
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Fig. 1. (a) Forest diagram depicting reporting odds ratio (ROR) and 95% conﬁdence intervals (95% CI) of cardiac adverse events associated with
carﬁlzomib reported in the FAERS database. (b) Cumulative Information Criterion values for selected adverse events associated with carﬁlzomib from
2017 to 2020.
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decreased endothelial nitric oxide synthase activity
and nitric oxide levels within the heart [22]; irreversible proteasome inhibition is associated with
better outcomes in MM than reversible proteasome
inhibition, but irreversible inhibition of endothelial
nitric oxide synthase likely produces a more pronounced decrease in nitric oxide levels than
reversible inhibition., However, the mechanisms of
the other adverse events, such as acute hypertension and QTc prolongation, remain unclear.
The study supports baseline cardiovascular risk
assessment, with electrocardiography and echocardiography, prior to treatment with carﬁlzomib.
Close monitoring for signs and symptoms of cardiac
failure, cardiac ischemia, arrhythmias, and QTc
prolongation is of utmost importance in patients
receiving this medication.
4.1. Limitations
Limitations of this study are primarily due to its
retrospective nature of the FAERS database. Due to
the nature of the database, information such as time
to event and grade of toxicity is occasionally not
reported. Because the database only contains
adverse reactions, patients without adverse reactions are not captured, so the exact denominator
of PI treated patients could not be determined. The
exact rates of adverse cardiac events cannot be
conclusively determined as all adverse events are
not reported in FAERS.

5. Conclusions
Carﬁlzomib and PIs in general have revolutionized
treatment for multiple myeloma. Unfortunately,
Carﬁlzomib and other PIs are associated with higher
risk of cardiotoxic adverse events. Awareness of this
increased cardiovascular risk may lead to baseline
cardiovascular risk assessment in all patients starting this therapy. Additionally, early diagnosis and
management of these cardiotoxicities may potentially minimize interruptions to the treatment.
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